Ethyreal Bio hits proof of mechanism for TSHR antibody ETHY-001

Ethyreal Bio has reported proof-of-mechanism data from Part A of its Phase 1 first-in-human trial of ETHY-001, a monoclonal antibody antagonist of the thyroid stimulating hormone receptor (TSHR). Results from healthy volunteers showed consistent, dose-dependent pharmacodynamic activity after a single subcutaneous injection, with a pharmacokinetic profile the Cambridge, Massachusetts company says could support dosing every three months or less frequently.

The company has now moved to the patient portion of the study, opening the first cohorts of individuals with thyroid eye disease (TED) and underlying Graves' disease (GD). ETHY-001 holds FDA Fast Track designation for TED, a status that provides more frequent agency interaction and eligibility for rolling review.

Clinical profile and mechanism

TSHR is the shared upstream driver of both GD and TED. Pathogenic autoantibodies activate the receptor, triggering excess thyroid hormone production in GD and inflammatory orbital changes in TED, the latter of which can cause proptosis, diplopia and, in severe cases, permanent vision loss. Current therapies address downstream consequences rather than the receptor itself; many GD patients ultimately require thyroid ablation or surgery.

ETHY-001 is designed to block autoantibody-mediated TSHR activation directly. In healthy volunteers, the company reported rapid onset of pharmacodynamic effect, evidenced by thyroid function test changes across dosing cohorts, alongside a clean safety read: no serious or severe adverse events were observed. The low-volume subcutaneous formulation incorporates half-life extension technology to achieve the extended dosing interval.

Chief executive Niranjan Kameswaran said the data provided "the first clinical validation of our differentiated approach to treating TSHR-driven disease" and positioned ETHY-001 as having "best-in-class potential" as development progresses into patients. The company is presenting ETHY-001 as potentially capable of treating both TED and GD through a single mechanism, which would differentiate it from condition-specific therapies in the current market.

Competitive landscape

The TED treatment space is small but increasingly active. Amgen's teprotumumab (Tepezza), an IGF-1R inhibitor approved by the FDA in 2020, established the first targeted therapy for TED but is administered by intravenous infusion and has been associated with hearing-related side effects and relapse rates that leave room for improvement. Horizon Therapeutics, now part of Amgen following a 2023 acquisition, has continued development work in the indication.

Several other TSHR-targeting approaches are in earlier preclinical and clinical development across academic and industry groups, as the receptor has become a validated target. A subcutaneous, quarterly-dosed antibody antagonist would offer a meaningful convenience advantage over the existing infusion-based standard of care if patient-cohort data replicate the tolerability and durability signals seen in healthy volunteers.

Graves' disease, which affects an estimated 1 to 2 per cent of the adult population, remains without an approved disease-modifying therapy. That broad unaddressed population represents the larger commercial opportunity and the higher clinical bar: Ethyreal will need to demonstrate not just TSHR engagement but meaningful clinical outcomes across the spectrum of disease severity as the trial progresses.

Key forthcoming milestones include patient-cohort safety and pharmacodynamic readouts, with the company expected to present data at a relevant endocrinology or ophthalmology congress. No Phase 2 timeline or financing update was included in the release.